There has been a slight increase in congestive heart failure risk in patients receiving Tixagevimab-cilgavimab when compared to the placebo group but this did not reach statistical significance.
← all excerpts
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders.
1
—
—